Get our latest issue now

available for iOS, Android & web

latest issue

UCB takes majority stake in Brazil's Meizler

Daily News | May 31, 2012

Kevin Grogan

UCB takes majority stake in Brazil's Meizler

UCB has expanded its presence in the emerging markets by acquiring a majority stake in Brazilian drugmaker Meizler Biopharma.

The Belgian group is taking an initial 51% stake in the privately-owned Sao Paulo-headquartered company. Under the terms of the deal, the financial details for which have not been disclosed, Meizler's owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% at some stage in the future.

Meizler, which was founded in 1990 and has 130 employees, sells in-licensed specialty products which cover different therapeutic categories, including central nervous system and immunology treatments, UCB's main areas of expertise. A profitable entity, sales last year topped 36 million euros.

UCB chief executive Roch Doliveux noted that "Brazil is one of UCB’s key markets in which the company did not have a direct presence". He added that  "we look forward to building our presence in this region", which is the seventh-largest biopharmaceutical market worldwide and "growing fast".

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!